Bio-Rad Laboratories (BIO): Assessing Valuation Following Q3 Loss and Share Buyback Completion

Simply Wall St.

2025/11/11

Bio-Rad Laboratories (BIO) released its third-quarter financial results, posting a net loss compared to a sizeable profit this time last year. The company also completed a major share repurchase ...

网页链接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2582233377"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582233377\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582233377?lang=zh_TW&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","is_english":true,"pubTime":"2025-11-11 10:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582233377","market":"sg","top_or_hot":-1,"title":"Bio-Rad Laboratories (BIO): Assessing Valuation Following Q3 Loss and Share Buyback Completion","media":"Simply Wall St.","content":"<div>\n<p>Bio-Rad Laboratories (BIO) released its third-quarter financial results, posting a net loss compared to a sizeable profit this time last year. The company also completed a major share repurchase ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bio/bio-rad-laboratories/news/bio-rad-laboratories-bio-assessing-valuation-following-q3-lo\">网页链接</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bio-Rad Laboratories (BIO): Assessing Valuation Following Q3 Loss and Share Buyback Completion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBio-Rad Laboratories (BIO): Assessing Valuation Following Q3 Loss and Share Buyback Completion\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Simply Wall St.</strong><span class=\"h-time small\">2025-11-11 10:24</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>Bio-Rad Laboratories (BIO) released its third-quarter financial results, posting a net loss compared to a sizeable profit this time last year. The company also completed a major share repurchase ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bio/bio-rad-laboratories/news/bio-rad-laboratories-bio-assessing-valuation-following-q3-lo\">网页链接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bio/bio-rad-laboratories/news/bio-rad-laboratories-bio-assessing-valuation-following-q3-lo\">Simply Wall St.</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BIO","symbol_name":"Bio Rad實驗室","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bio/bio-rad-laboratories/news/bio-rad-laboratories-bio-assessing-valuation-following-q3-lo","article_id":"2582233377","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bio/bio-rad-laboratories/news/bio-rad-laboratories-bio-assessing-valuation-following-q3-lo","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2582233377","pubTimestamp":1762827843,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Bio-Rad Laboratories (BIO) released its third-quarter financial results, posting a net loss compared to a sizeable profit this time last year. The company also completed a major share repurchase initiative during the quarter, adding another dimension for investors to consider.\nSee our latest analysis for Bio-Rad Laboratories.\nDespite the challenging quarterly results and the latest share buyback, Bio-Rad Laboratories’ share price has shown a bit of a rebound recently, with an 11.9% share...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BIO":"Bio Rad实验室","BK4121":"生命科学工具和服务","BIO.AU":"BIOME AUSTRALIA LTD","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","BK7111":"个人用品","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","BIO.B":"Bio-Rad Laboratories Inc Cl B","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"Bio-Rad Laboratories(BIO)：评估第三季度亏损和股票回购完成后的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIO":1,"BIO.AU":1.5,"BIO.B":0.9},"content_text":"Bio-Rad Laboratories (BIO) released its third-quarter financial results, posting a net loss compared to a sizeable profit this time last year. The company also completed a major share repurchase initiative during the quarter, adding another dimension for investors to consider. See our latest analysis for Bio-Rad Laboratories. Despite the challenging quarterly results and the latest share buyback, Bio-Rad Laboratories’ share price has shown a bit of a rebound recently, with an 11.9% share price return over the past 90 days. However, momentum remains subdued over the long term, as the company’s 1-year total shareholder return lags at -16.0%. The 5-year figure stands at -48.5%, suggesting that investors remain cautious while waiting for clearer signs of a turnaround. If you’re curious about other healthcare companies navigating shifting market conditions, it’s a perfect moment to explore See the full list for free. The recent swing in financials and a completed share repurchase raise an important question: Is Bio-Rad Laboratories currently undervalued after its declines, or is the market already factoring in its future growth prospects and challenges? AdvertisementMost Popular Narrative: 5.1% Undervalued Bio-Rad Laboratories’ most closely followed narrative estimates a fair value of $324, which is just over 5% above the recent close of $307.38. This sets the stage for a debate about whether future growth and new partnerships are enough to push the shares higher.  Recent launch and expansion of the QX Continuum and QX700 Series ddPCR platforms, alongside the acquisition of Stilla Technologies, positions Bio-Rad to accelerate its share capture as demand grows for advanced molecular diagnostics and precision medicine tools. This is expected to drive ddPCR revenue growth and improve margins through higher consumable pull-through and broader assay adoption.  Read the complete narrative. Curious what’s behind this upward revision? There are bold assumptions about margin expansion and how new technologies could fuel long-term profitability. The full narrative unveils the numbers that could change how you see this valuation. Result: Fair Value of $324 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, persistent weakness in instrument demand and ongoing margin pressures could quickly challenge the optimism that is reflected in these valuation assumptions. Find out about the key risks to this Bio-Rad Laboratories narrative.  Build Your Own Bio-Rad Laboratories Narrative Keep in mind, if you have a different perspective or want to dive into the numbers yourself, you can build your own narrative in just a few minutes: Do it your way A good starting point is our analysis highlighting 3 key rewards investors are optimistic about regarding Bio-Rad Laboratories. Looking for More Smart Investment Opportunities? Don’t miss your chance to get ahead. Use the Simply Wall Street Screener now and seize investments others might overlook. These fresh opportunities could transform your portfolio’s trajectory:  Unlock great value potential by checking out these 864 undervalued stocks based on cash flows for stocks trading below their intrinsic worth. Boost your passive income stream and see which companies are offering impressive yields through these 16 dividend stocks with yields > 3%. Ride the next AI-driven growth wave by targeting innovators highlighted via these 25 AI penny stocks.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Bio-Rad Laboratories might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}